Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients

International Journal of Cancer

Volumn 66, Issue 4, 1996, Pages 477-483

  Tibben, Jacoba G ^a   Boerman, Otto C ^a   Massuger, Leon F A G ^a   Schijf, Charles P T ^a   Claessens, Roland A M J ^a   Corstens, Frans H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 2; IODINE 123; METOCLOPRAMIDE; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CARRIER PROTEINS; CYSTADENOMA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029991804     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960516)66:4<477::AID-IJC11>3.0.CO;2-5     Document Type: Article

References (24)

1. ABRAMOWICZ, D., SCHANDENE, L., GOLDMAN, M., CRUSIAUX, A., VEREERSTRAETEN, P., DE PAUW, L., WYBRAN, J., KINNAERT, P., DUPONT, E. and TOUSSAINT, C., Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney-transplant recipients. Transplantation, 47, 606-608 (1989).
2. BLANK-VOORTHUIS, C.J.A.C., BRAAKMAN, E., RONTELTAP, C.P.M., TILLY, B.C., STURM, E., WARNAAR, S.O. and BOLHUIS, R.L.H., Clustered CD3/TCR complexes do not transduce activation signals after bispecific-monoclonal-antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol., 151, 2904-2914 (1993).
3. BOLHUIS, R.L.H., LAMERS, C.H.J., GOEY, S.H., EGGERMONT, A.M.M., TRIMBOS, J.B.M.Z., STOTER, G., LANZAVECCHIA, A., DI RE, E., MIOTTI, S., RASPAGILIESI, F., RIVOLTINI, L. and COLNAGHI, M.I., Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int. J. Cancer, Suppl. 7, 78-81 (1992).
4. 1 lymphoma with bispecific antibodies. J. Immunol., 147, 4019-4026 (1991).
5. BUIJS, W.C.A.M., MASSUGER, L.F.A.G., CLAESSENS, R.A.M.J., KENEMANS, P. and CORSTENS, F.H.M., Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal-antibody fragments in patients with ovarian cancer. J. nucl. Med., 33, 1113-1120 (1992).
6. 2 fragments in ovarian-carcinoma patients. Cancer Res., 53, 5413-5418 (1993).
7. CAMPBELL, I.G., JONES, T.A., FOULKES, W.D. and TROWSDALE, J., Folate-binding protein is a marker for ovarian cancer. Cancer Res., 51, 5329-5338 (1991).
8. FRAKER, P.J. and SPECK, J.C., Protein and cell-membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem. biophys. Res. Commun., 80, 849-857 (1978).
9. ICRP, Report of the Task Group on reference man, Publication 23, Pergamon Press, Oxford (1975).
10. KROESEN, B.J., BUTER, J., SLEIJFER, D.T., JANSSEN, R.A.J., VAN DER GRAAF, W.T.A., THE, T.H., DE LEIJ, L. and MULDER, N.H., Phase-I study of intravenously applied bispecific antibody in renal-cell-cancer patients receiving subcutaneous interleukin 2. Brit. J. Cancer, 70, 652-661 (1994).
11. KROESEN, B.J., TER HAAR, A., SPAKMAN, H., WILLEMSE, P., SLEIJFER, D.T., DE VRIES E.G.E., MULDER, N.H., BERENDSEN, H.H., LIMBURG, P.C., THE, T.H. and DE LEIJ, L., Local anti-tumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother., 37, 400-407 (1993).
12. LINDMO, T., BOVEN, E., CUTTILA, F., FEDORKO, J. and BUNN, P.A., JR., Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Meth., 72, 77-89 (1984).
13. MIOTTI, S., CANEVARI, S., MENARD, S., MEZZANZANICA, D., PORRO, G., PUPA, S.M., REGAZZONI, M., TAGLIABUE, E. and COLNAGHI, M.J., Characterization of human ovarian-carcinoma-associated antigens defined by novel monoclonal antibodies with tumour-restricted specificity. Int. J. Cancer, 39, 297-303 (1987).
14. PEREZ, P., HOFFMAN, R.W., SHAW, S., BLUESTONE, J.A. and SEGAL, D.M., Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target-cell antibody. Nature (Lond.), 316, 354-356 (1985).
15. PEREZ, P., TITUS, J.A., LOTZE, M.T., CUTTITA, F., LONGO, D.L., GROVES, E.S., RABIN, H., DURDA, P.J. and SEGAL, D.M., Specific lysis of human tumour cells by T cells coated with anti-T3 cross-linked to anti-tumour antibody. J. Immunol., 137, 2069-2072 (1986).
16. PUPA, S.M., CANEVARI, S., FONTANELLI, R., MENARD, S., MEZZANZANICA, D., LANZAVECCHIA, A. and COLNAOHI, M.I., Activation of mononuclear cells to be used for hybrid monoclonal-antibody-induced lysis of human ovarian-carcinoma cells. Int. J. Cancer, 42, 455-459 (1988).
17. RENNER, C., JUNG, W., SAHIN, U., DENFELD, R., POHL, C., TRUMPER, L., HARTMANN, F., DIEHL, V., VAN LIER, R. and PFREUNDSHUH, M., Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science, 264, 833-835 (1994).
18. SEGAL, D.M., QIAN, J.H., ANDREW, S.M., TITUS, J.A., MEZZANZANICA, D., GARRIDO, M.A. and WUNDERLICH, J.R., Cytokine release by peripheral lymphocytes targeted with bispecific antibodies, and its role in blocking tumor growth. Ann. N. Y.Acad. Sci., 636, 288-294 (1991).
19. 2 in experimental ovarian cancer. Europ. J. nucl. Med., 21, 1183-1190 (1994).
20. TITUS, J.A., GARRIDO, M.A., HECHT, T.T., WINKLER, D.F., WUNDERLICH, J.R. and SEGAL, D.M., Human T cells targeted with anti-T3 cross-linked to anti-tumor antibody prevent tumor growth in nude mice. J. Immunol., 138, 4018-4022 (1987).
21. VAN RAVENSWAAY CLAASEN, H.H., VAN DE GRIEND, R.J., MEZZANZANICA, D., BOLHUIS, R.L.H., WARNAAR, S.O. and FLEUREN, G.J., Analysis of production, purification and cytolytic potential of bispecific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int. J. Cancer, 55, 128-136 (1993).
22. VAN RAVENSWAAY CLAASEN, H.H., EGGERMONT, A.M.M., NOOYEN, Y.A., WARNAAR, S.O. and FLEUREN, G.J., Immunotherapy in a human ovarian-cancer-xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR. Gynecol. Oncol., 52, 199-206 (1994).
23. WEINER, G.J., KOSTELNY, S.A., HILSTROM, J.R., COLE, M.S., LINK, B.K., WANG, S.L. and Tso, J.Y., The role of T-cell activation in anti-CD3 × anti-tumor bispecific-antibody therapy. J. Immunol., 152, 2385-2392 (1994).
24. WEITMAN, S.D., LARK, R.H., CONEY, L.R., FORT, D.W., FRASCA, V., ZURAWSKI, V.R., JR. and KAMEN, B.A., Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res., 52, 3396-3401 (1992).